

References

1. Streiner D. [The 2 “Es” of Research: Efficacy and Effectiveness Trials.](#) Can J Psychiatry. 2002;47:552–6.
2. Schwartz D, Lelouch J. [Explanatory and pragmatic attitudes in therapeutical trials.](#) J Chronic Dis. 1967 Aug;20(8):637–48.
3. Sedgwick P. [Explanatory trials versus pragmatic trials.](#) BMJ. 2014 Nov 13;349:g6694.
4. Zwarenstein M. ‘Pragmatic’ and ‘Explanatory’ attitudes to randomized trials. James Lind Libr [Internet]. [cited 2018 Jan 18]; Available from: <http://www.jameslindlibrary.org/articles/pragmatic-and-explanatory-attitudes-to-randomized-trials/>
5. Sackett DL. [Explanatory and pragmatic clinical trials: a primer and application to a recent asthma trial.](#) Pol Arch Med Wewn. 2011 Aug;121(7–8):259–63.
6. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. [A simple and valid tool distinguished efficacy from effectiveness studies.](#) J Clin Epidemiol. 2006 Oct 1;59(10):1040–8.
7. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. [The PRECIS-2 tool: designing trials that are fit for purpose.](#) BMJ. 2015 May 8;350:h2147.
8. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. [Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis.](#) Lancet Lond Engl. 1998 Oct 24;352(9137):1340–3.
9. Ferguson GG, Eliasziw M, Barr HWK, Clagett GP, Barnes RW, Wallace MC, et al. [The North American Symptomatic Carotid Endarterectomy Trial: Surgical Results in 1415 Patients.](#) Stroke. 1999 Sep 1;30(9):1751–8.
10. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. [A pragmatic-explanatory continuum indicator summary \(PRECIS\): a tool to help trial designers.](#) CMAJ Can Med Assoc J. 2009 May 12;180(10):E47–57.